Arcoma AB

OM:ARCOMA Stock Report

Market Cap: SEK 151.0m

Arcoma Future Growth

Future criteria checks 3/6

Arcoma is forecast to grow earnings and revenue by 7.9% and 8.3% per annum respectively. EPS is expected to grow by 9% per annum. Return on equity is forecast to be 20.3% in 3 years.

Key information

7.9%

Earnings growth rate

9.0%

EPS growth rate

Medical Equipment earnings growth35.8%
Revenue growth rate8.3%
Future return on equity20.3%
Analyst coverage

Low

Last updated25 Oct 2024

Recent future growth updates

Recent updates

Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Nov 09
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop

Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

Aug 22
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Aug 07
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26
Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06
Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Is Arcoma (STO:ARCOMA) A Risky Investment?

Jan 15
Is Arcoma (STO:ARCOMA) A Risky Investment?

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Sep 11
We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Jun 08
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Apr 27
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Dec 22
Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

May 03
Is Arcoma (STO:ARCOMA) Using Too Much Debt?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Oct 28
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Is Arcoma (STO:ARCOMA) A Risky Investment?

Mar 17
Is Arcoma (STO:ARCOMA) A Risky Investment?

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Feb 04
Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14
Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21
Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Earnings and Revenue Growth Forecasts

OM:ARCOMA - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262071717221
12/31/20251941512171
12/31/2024178168131
9/30/2024171132428N/A
6/30/2024175131922N/A
3/31/202417291921N/A
12/31/202316331719N/A
9/30/20231530-13N/A
6/30/20231460-23N/A
3/31/2023138128N/A
12/31/20221252-40N/A
9/30/2022105-658N/A
6/30/202299-1002N/A
3/31/2022105-11-11-8N/A
12/31/2021117-7-6-2N/A
9/30/2021126-6-10-7N/A
6/30/2021125-2-7-2N/A
3/31/2021121-1-60N/A
12/31/20201171-57N/A
9/30/20201228-142N/A
6/30/202013010320N/A
3/31/202013210218N/A
12/31/20191347011N/A
9/30/20191335511N/A
6/30/20191322-32N/A
3/31/2019129114N/A
12/31/2018119-2-10N/A
9/30/2018111-1-3-1N/A
6/30/201898-6N/A-11N/A
3/31/201894-10N/A-8N/A
12/31/201792-10N/A-9N/A
9/30/201798-9N/A0N/A
6/30/2017108-4N/A3N/A
3/31/2017106-5N/A0N/A
12/31/2016102-12N/A-5N/A
9/30/2016106-12N/A-12N/A
6/30/2016105-13N/A-9N/A
3/31/2016104-15N/A-17N/A
12/31/2015123-6N/A-5N/A
9/30/2015117-6N/A-4N/A
6/30/2015119-5N/A-2N/A
3/31/20151331N/A5N/A
12/31/20141301N/A-1N/A
9/30/2014134-7N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARCOMA's forecast earnings growth (7.9% per year) is above the savings rate (1.2%).

Earnings vs Market: ARCOMA's earnings (7.9% per year) are forecast to grow slower than the Swedish market (14.3% per year).

High Growth Earnings: ARCOMA's earnings are forecast to grow, but not significantly.

Revenue vs Market: ARCOMA's revenue (8.3% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: ARCOMA's revenue (8.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARCOMA's Return on Equity is forecast to be high in 3 years time (20.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 23:04
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arcoma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hjalmar JernstromPenser Access